MedTrace Logo

A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors

NCT03070301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2024-10-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.

Conditions

Interventions

DRUG

LEE011

LEE011 200 mg daily

DRUG

everolimus

everolimus 5 mg daily or 2.5mg daily

Sponsors & Collaborators

Principal Investigators

  • Diane Reidy-Lagunes, MD, MS · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-27
Primary Completion
2024-01-31
Completion
2024-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03070301 on ClinicalTrials.gov